File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma

TitleApplication of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma
Authors
KeywordsEBER1
Distant metastasis
BamH1-W
TaqMan quantitative real time PCR
Plasma EBV DNA
Local recurrence
Nasopharyngeal Cancer
Head and Neck cancer
Epstein-Barr virus
EBNA1
Issue Date2014
Citation
Oral Oncology, 2014, v. 50, n. 6, p. 527-538 How to Cite?
AbstractElevated levels of circulating cell-free Epstein-Barr virus (EBV) DNA have been detected in plasma and serum samples from nasopharyngeal cancer (NPC) patients by quantitative real time PCR (qPCR) test. This qPCR test for circulating EBV DNA was found to be useful in the clinical management of NPC patients. For instance, EBV DNA qPCR test has good sensitivity and specificity in the detection of NPC at disease onset. Increase of the viral DNA load was found in NPC patients at late stages of disease. High EBV DNA load at disease onset or detectable viral load post-treatment was associated with poor survival or frequent relapse in NPC patients. Residual EBV DNA load after primary treatment could be a useful indicator to justify adjuvant chemotherapy. The qPCR test might also be applied to define a poor prognostic group in patients at early stage (I/II) for implementing concurrent chemo-radiotherapy (chemo-RT) to improve patients' outcome. The test is also useful to monitor distant metastases or response to radiotherapy, chemo-RT or surgery. Supplementary tests, however, are needed to pick up EBV negative WHO type I NPC and test improvement is needed to increase sensitivity in detecting stage I disease and local recurrence. © 2013 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/251667
ISSN
2020 Impact Factor: 5.337
2020 SCImago Journal Rankings: 1.623
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYip, Timothy T.C.-
dc.contributor.authorNgan, Roger K.C.-
dc.contributor.authorFong, Alvin H.W.-
dc.contributor.authorLaw, Stephen C.K.-
dc.date.accessioned2018-03-08T05:00:37Z-
dc.date.available2018-03-08T05:00:37Z-
dc.date.issued2014-
dc.identifier.citationOral Oncology, 2014, v. 50, n. 6, p. 527-538-
dc.identifier.issn1368-8375-
dc.identifier.urihttp://hdl.handle.net/10722/251667-
dc.description.abstractElevated levels of circulating cell-free Epstein-Barr virus (EBV) DNA have been detected in plasma and serum samples from nasopharyngeal cancer (NPC) patients by quantitative real time PCR (qPCR) test. This qPCR test for circulating EBV DNA was found to be useful in the clinical management of NPC patients. For instance, EBV DNA qPCR test has good sensitivity and specificity in the detection of NPC at disease onset. Increase of the viral DNA load was found in NPC patients at late stages of disease. High EBV DNA load at disease onset or detectable viral load post-treatment was associated with poor survival or frequent relapse in NPC patients. Residual EBV DNA load after primary treatment could be a useful indicator to justify adjuvant chemotherapy. The qPCR test might also be applied to define a poor prognostic group in patients at early stage (I/II) for implementing concurrent chemo-radiotherapy (chemo-RT) to improve patients' outcome. The test is also useful to monitor distant metastases or response to radiotherapy, chemo-RT or surgery. Supplementary tests, however, are needed to pick up EBV negative WHO type I NPC and test improvement is needed to increase sensitivity in detecting stage I disease and local recurrence. © 2013 Elsevier Ltd. All rights reserved.-
dc.languageeng-
dc.relation.ispartofOral Oncology-
dc.subjectEBER1-
dc.subjectDistant metastasis-
dc.subjectBamH1-W-
dc.subjectTaqMan quantitative real time PCR-
dc.subjectPlasma EBV DNA-
dc.subjectLocal recurrence-
dc.subjectNasopharyngeal Cancer-
dc.subjectHead and Neck cancer-
dc.subjectEpstein-Barr virus-
dc.subjectEBNA1-
dc.titleApplication of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.oraloncology.2013.12.011-
dc.identifier.pmid24440146-
dc.identifier.scopuseid_2-s2.0-84900488822-
dc.identifier.volume50-
dc.identifier.issue6-
dc.identifier.spage527-
dc.identifier.epage538-
dc.identifier.eissn1879-0593-
dc.identifier.isiWOS:000335889000002-
dc.identifier.issnl1368-8375-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats